Reo to Receive Approval for Second COVID Vaccine Before Clinical Trial Completion... "Approval Expected After Phase 2 Clinical Trial"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Hyunwoo Lee] Russia's second novel coronavirus disease (COVID-19) vaccine under development is expected to be approved immediately after only Phase 2 clinical trials, similar to the previously approved Sputnik V vaccine, raising concerns about safety.

According to TASS news agency, the Vector Research Center, a national virus and biotechnology institute located in Novosibirsk, Siberia, which has been developing a COVID-19 vaccine together with the Russian state Gamaleya Institute, is also expected to receive approval after Phase 2 clinical trials. Alexander Ryzhikov, head of the Department of Zoonotic Infectious Diseases and Influenza at the Vector Research Center, stated in an interview with the Russian TV channel Rossiya 24 on the 27th (local time) that "Phase 3 clinical trials will be conducted after government approval and registration."

Director Ryzhikov said that the vaccine developed by the Vector Center is currently in Phase 2 clinical trials, and an evaluation of the Phase 2 results involving 100 participants will be available by mid-September. The official registration of the Vector vaccine is expected to take place in October, after which mass production will begin immediately, and the first batch of vaccines is scheduled to be produced between late October and November.

Generally, vaccines undergo Phase 3 clinical trials, which verify that the vaccine does not harm a large number of recipients, before registration and approval. However, in Russia, the previously developed Sputnik V vaccine was approved by skipping Phase 3 clinical trials and has currently entered Phase 3 trials after approval.

This content was produced with the assistance of AI translation services.